Cancer Genetics Other Current Assets

Cancer Genetics posts a other current assets of $880K as of December 2020. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Other Current Assets is one piece of Cancer Genetics's financial statement story. At $880K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CGIX's other current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Cancer Genetics's other metric pages and overview cover the third.

Judging Cancer Genetics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other current assets easier to interpret. Start with $880K here, then scan peer and history charts to see if the gap is persistent.